ABcann Medicinals Inc (ABCN)

[NetworkNewsWire]

ABCN Announces Appointment of Dr. Michael Shannon as Chief Medical Consultant

On Thursday, ABcann Global Corporation (TSXV: ABCN) announced that it has retained the services of Dr. Michael Shannon as its chief medical consultant. Shannon brings decades of health care experience to the ABcann team, including time in both the private and public sectors. Among Shannon’s career highlights, in 1996, he assumed responsibilities within Health Canada for re-organizing the Canadian blood system and the development of a new corporate entity dedicated exclusively to the management of blood services in Canada. In 2000, he entered the private sector, simultaneously directing a phase III clinical trial in Canada, the United States and Great Britain for an artificial blood substitute product. “In the future we plan to participate in a number of clinical trials involving different modes of delivery as well as various research projects with potentially significant clinical implications in order to facilitate the acceptance of cannabis treatment by the mainstream medical community,” Aaron Keay, CEO of ABcann, noted in the news release. “Dr. Shannon’s experience and expertise, along with his established credibility, will help us through this process as we move these developments forward.”

To view the full press release, visit http://nnw.fm/VvN12

About ABcann Global Corporation

ABcann was one of the first companies to obtain a production license under the Marijuana for Medical Purposes Regulations, which it received on March 21, 2014. It obtained a sales license on December 31, 2015. ABcann’s flagship facility, in Napanee, Ontario, contains proprietary plant-growing technology, including environmentally-controlled chambers capable of monitoring and regulating all variables in the growing process. This approach and the systems in place allow ABcann to produce organically grown and pesticide-free, high-yielding plants, which, in turn, can generate high-quality products that are consistent from batch to batch. ABcann is able to control environmental and nutrient demands, tailor-made for a particular strain of cannabis, without the variation that is typical when producing large quantities in less-controlled, larger rooms and greenhouse-type structures. ABcann’s modular approach to systems technology eliminates scale-up risk and allows ABcann to locate anywhere in the world and maintain consistency and quality of product. For more information, visit www.ABcannGlobal.com